Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,105 JPY | -1.27% | +2.78% | +20.29% |
2023 | Kakuyasu Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
2021 | COSMOS Pharmaceutical : Topix closes at near one-month high as investors await earnings | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.74 for the current year.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.2 for the 2024 fiscal year.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Food Retail & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.29% | 129M | - | ||
-2.69% | 6.04B | C | ||
-0.44% | 1.03B | - | ||
+8.11% | 400M | - | - | |
+3.54% | 341M | - | - | |
+2.46% | 216M | - | - | |
-19.68% | 176M | - | - | |
+16.62% | 109M | - | - | |
-13.16% | 66.01M | - | - | |
-25.71% | 52.85M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 7686 Stock
- Ratings Kakuyasu Group Co., Ltd.